Obesity originates from a complex interplay of genetic, environmental, behavioral, and metabolic factors. Genetic predisposition can influence appetite regulation and energy metabolism. Environmental changes, characterized by increased availability of high-calorie foods and decreased physical activity due to modern conveniences, facilitate positive energy balance. Behavioral factors, including poor diet and inactivity, compounded by psychological influences such as stress-eating, further promote excess body weight. Endocrine imbalances, seen in conditions like hypothyroidism and PCOS, also contribute to weight gain and maintenance. Understanding these multifaceted interactions highlights obesity as a chronic, relapsing disease, complicating treatment and necessitating comprehensive management strategies .

BMI presents significant challenges as an obesity assessment tool because it does not differentiate between fat and lean body mass, leading to potential misclassification. Muscular individuals may be classified as overweight or obese due to high body mass despite low fat levels. Conversely, individuals with low muscle mass but high body fat might be classified as normal, underestimating health risks. BMI also fails to account for fat distribution, which is crucial for determining metabolic and cardiovascular risks, thus limiting its utility in comprehensive risk assessment .

Lifestyle interventions are crucial in managing obesity, encompassing dietary changes, physical activity, and behavioral therapy. Effectively reducing caloric intake through balanced diets like the Mediterranean or tailored low-carbohydrate plans can significantly aid weight loss. Regular physical activity, aimed at 150–300 minutes of moderate-intensity exercise per week, helps maintain weight loss by increasing energy expenditure. Behavioral therapy, including cognitive-behavioral strategies, supports habit change and long-term adherence, increasing the chances of sustained weight management. These combined approaches are generally effective when adhered to, but require patient motivation and often additional support for optimal success .

Current pharmacologic treatments for obesity include agents like Orlistat, Liraglutide, Semaglutide, and the combination of Naltrexone/Bupropion, each with distinct mechanisms. Orlistat inhibits lipases, reducing fat absorption in the intestines. GLP-1 receptor agonists like Liraglutide and Semaglutide act centrally to decrease appetite and delay gastric emptying. Naltrexone/Bupropion targets brain pathways involved in reward-related eating behaviors, reducing cravings and increasing energy expenditure. These medications aim to support weight loss in conjunction with lifestyle changes, particularly for individuals with high BMI and comorbid conditions .

Environmental factors have significantly contributed to the global obesity epidemic by creating an obesogenic environment. Urbanization and the widespread availability of processed and high-calorie foods have increased energy intake, while modern lifestyle changes have reduced physical activity through sedentary jobs and reliance on motorized transport. Socioeconomic disparities further exacerbate the issue, as they influence food choices and access to recreational activities. Together, these factors have increased the prevalence of obesity by facilitating a positive energy balance—consuming more calories than expended .

Hormonal imbalances, particularly involving leptin and adiponectin, contribute significantly to obesity's pathophysiology. Leptin, secreted by adipocytes, signals the brain to regulate hunger, but in obesity, despite high levels of leptin, the brain becomes resistant to its effects, leading to continued overeating and decreased energy expenditure. Conversely, adiponectin levels, which enhance insulin sensitivity and have anti-inflammatory properties, are inversely related to fat mass. Low levels of adiponectin in obese individuals further exacerbate metabolic dysfunction, contributing to insulin resistance and associated complications .

Genetic factors play a significant role in body weight regulation, with research indicating that 40–70% of the BMI variance can be attributed to heritability. Studies on twins and adoptees have shown these strong genetic influences. One key genetic factor is the FTO (fat mass and obesity-associated) gene, where specific variants are linked to increased appetite and preference for high-energy foods, contributing to higher body weight. These findings underscore genetics as a crucial component in understanding obesity risk .

Obesity significantly increases risks for various health conditions, particularly cardiovascular diseases. It accelerates atherosclerosis, raises blood pressure (hypertension), and is linked with dyslipidemia, creating conditions conducive to heart attack, stroke, and heart failure. Central obesity exacerbates these risks due to its association with higher visceral fat, which more actively contributes to systemic inflammation and metabolic disturbances, further increasing cardiovascular disease risk .

Android fat distribution, characterized by excess fat around the abdomen, is associated with higher risks of metabolic syndrome, insulin resistance, type 2 diabetes, and cardiovascular diseases, making it particularly detrimental metabolically. This pattern is more common in men and carries a greater health risk due to the higher presence of visceral fat, which more actively releases pro-inflammatory cytokines contributing to these conditions. In contrast, gynoid fat distribution, with fat stored primarily around the hips and thighs, is less harmful and more typical in premenopausal women, posing a lower risk for metabolic disorders .

Insulin resistance is a crucial biochemical mechanism contributing to obesity, particularly in those with central adiposity. In such cases, adipose tissue secretes pro-inflammatory cytokines like TNF-α and IL-6, impairing insulin signaling pathways. This results in hyperinsulinemia and increased hepatic glucose production, promoting fat storage and further exacerbating obesity-related metabolic disturbances. Insulin resistance thus fosters a cycle of metabolic dysfunction, heightening the risk for type 2 diabetes and other associated complications .